Trial · NCT02450331
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-Free Survival (DFS), as Assessed by Investigator | Observation | 16.6 | 95% Confidence Interval 11.2 to 24.8 | Months | |
| Disease-Free Survival (DFS), as Assessed by Investigator | Atezolizumab | 19.4 | 95% Confidence Interval 15.9 to 24.8 | Months | |
| Overall Survival (OS) | Observation | 59.0 | 95% Confidence Interval 47.7 to NA | Months | |
| Overall Survival (OS) | Atezolizumab | 61.4 | 95% Confidence Interval 47.0 to NA | Months | |
| Disease-Specific Survival (DSS), as Assessed by Investigator | Observation | NA | 95% Confidence Interval NA to NA | Months | |
| Disease-Specific Survival (DSS), as Assessed by Investigator | Atezolizumab | NA | 95% Confidence Interval NA to NA | Months | |
| Distant Metastasis-Free Survival (DMFS) | Observation | 31.1 | 95% Confidence Interval 21.7 to 41.4 | Months | |
| Distant Metastasis-Free Survival (DMFS) | Atezolizumab | 27.5 | 95% Confidence Interval 22.6 to NA | Months | |
| Non-Urinary Tract Recurrence-Free Survival (NURFS) | Observation | 19.5 | 95% Confidence Interval 12.3 to 27.7 | Months | |
| Non-Urinary Tract Recurrence-Free Survival (NURFS) | Atezolizumab | 22.1 | 95% Confidence Interval 17.2 to 27.6 | Months | |
| Percentage of Participants With Adverse Events (AEs) | Observation | 79.1 | Percentage of Participants | ||
| Percentage of Participants With Adverse Events (AEs) | Atezolizumab | 94.4 | Percentage of Participants | ||
| Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | Atezolizumab | 29.3 | Percentage of Participants | ||
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Observation | Cycle 1 Day 1 | 77.41 | Standard Deviation 15.74 | Score on scale |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Atezolizumab | Cycle 1 Day 1 | 78.89 | Standard Deviation 16.13 | Score on scale |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Observation | Cycle 3 Day 1 | 78.64 | Standard Deviation 15.73 | Score on scale |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Atezolizumab | Cycle 3 Day 1 | 81.05 | Standard Deviation 14.96 | Score on scale |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Observation | Cycle 5 Day 1 | 79.94 | Standard Deviation 16.32 | Score on scale |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Atezolizumab | Cycle 5 Day 1 | 81.95 | Standard Deviation 14.32 | Score on scale |
| EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score | Observation | Cycle 7 Day 1 | 80.81 | Standard Deviation 16.37 | Score on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02450331/results